South-East Asia (WHO region) vs United States: Treatment success rate: XDR-TB cases
South-East Asia (WHO region)
73
in 2022
United States
100
in 2021
South-East Asia (WHO region) rank
2nd
United States rank
1st
Treatment success rate: XDR-TB cases over time
- South-East Asia (WHO region)
- United States
How they compare
United States currently reports 100 against 73 in South-East Asia (WHO region), a difference of 27.
That makes United States's figure about 1.4 times South-East Asia (WHO region)'s.
The two have swapped places 4 times across 9 shared years of data; in 2011 it was United States ahead.
South-East Asia (WHO region) ranks 2nd and United States ranks 1st of 11 groups.
Across the 2 decades both report, South-East Asia (WHO region) averaged higher in 1 and United States in 1.
Head to head by decade
| Decade | South-East Asia (WHO region) | United States | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 35.71 | 78.29 | 42.57 | United States |
| 2020s | 67 | 50 | 17 | South-East Asia (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate: xdr-tb cases, South-East Asia (WHO region) or United States?
- United States, at 100 against 73 in South-East Asia (WHO region) as of 2021.
- What is the difference in treatment success rate: xdr-tb cases between South-East Asia (WHO region) and United States?
- 27, with United States ahead.
- How many years of comparable data are there for South-East Asia (WHO region) and United States?
- 9 years are reported by both, from 2011 to 2021.
- How do South-East Asia (WHO region) and United States rank globally for treatment success rate: xdr-tb cases?
- South-East Asia (WHO region) ranks 2nd and United States ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate: XDR-TB cases. Statizoid refreshes it automatically from the source and publishes the full history for both places.